FIELD : chemistry.SUBSTANCE : invention refers to organic chemistry and medicine. Disclosed is use of a tetraacetyled derivative of 5-amino-4-carbamoylimidazolyl-1-β-D-ribofuranoside – ((AcO)4AICAR) as a selective inhibitor of protein kinase Cδ. (AcO)4AICAR effectively inhibits protein kinase Cδ (PKCδ) due to specific inhibition of PKCδ/NF-κB signaling pathway.EFFECT : because (AcO)4AICAR does not possess high toxicity with respect to healthy cells, it allows using it in disturbances prevention of PKCδ/NF-κB signaling pathway, for example to prevent apoptosis or increased thrombosis.4 cl, 4 dwg, 6 ex